{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:54:52Z","timestamp":1781456092627,"version":"3.54.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prosthetic vascular graft infection (PVGI) is a rare but life-threatening complication. Graft replacement is the only curative option, but often unfeasible due to high mortality risk. Suppressive antimicrobial therapy (SAT) offers a viable alternative, though evidence on regimens and duration is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study, reviewing records of PVGI patients during 2014\u20132025 aiming to evaluate the efficacy of SAT. SAT was considered effective when allowing infection control under treatment; patients were defined as cured if no relapse occurred after at least 6 months from discontinuation. Patients were classified according to the Management of Aortic Graft Infection Collaboration criteria and managed by a multidisciplinary team.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty patients met the inclusion criteria; 5 underwent graft removal and 25 underwent SAT. Infections were diagnosed a median of 90 [30\u20131095] days postsurgery. Fever occur in 15\/25 (60%) and abscess in 12\/25 (48%) patients. Microbiological diagnosis was achieved in 17\/25 (68%) cases. A long-acting antibiotic (LAA) was used in 6\/25 (24%), with successful discontinuation in 3\/6. Drug adverse events occurred in 8\/25 (32%) patients and treatment failure was observed in 11 among all antibiotic regimens analyzed. Infection control during SAT was achieved in 10 (40%) patients. Ten patients discontinued SAT and 6\/10 (60%) remained relapse-free after more than 6 months of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SAT is a valuable option for high-risk PVGI patients. LAA may represent an option. PET\/CT remains key for diagnosis and monitoring. Further studies are needed to define optimal SAT duration and to improve long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag327","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:44:16Z","timestamp":1780573456000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Suppressive Antimicrobial Therapy in Prosthetic Vascular Graft Infection: A Retrospective Evaluation of a Cohort of Patients Enrolled at Tor Vergata Hospital in Rome"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0322-7277","authenticated-orcid":false,"given":"Alessandra","family":"Imeneo","sequence":"first","affiliation":[{"name":"Infectious Diseases, Department of Systems Medicine, Tor Vergata University , Rome ,","place":["Italy"]},{"name":"National Institute for Infectious Diseases \u201cL. Spallanzani\u201d IRCCS Clinical and Research Infectious Diseases Department, , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-6800","authenticated-orcid":false,"given":"Drieda","family":"Za\u00e7e","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Systems Medicine, Tor Vergata University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8081-807X","authenticated-orcid":false,"given":"Fabio Massimo","family":"Oddi","sequence":"additional","affiliation":[{"name":"Vascular and Endovascular Surgery, Department of Biomedicine and Prevention, Tor Vergata University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6281-8668","authenticated-orcid":false,"given":"Grazia","family":"Alessio","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Systems Medicine, Tor Vergata University , Rome ,","place":["Italy"]},{"name":"National Institute for Infectious Diseases \u201cL. Spallanzani\u201d IRCCS Clinical and Research Infectious Diseases Department, , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Systems Medicine, Tor Vergata University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8761-6267","authenticated-orcid":false,"given":"Tiziana","family":"Mulas","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinic, Policlinico Tor Vergata , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Crea","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinic, Policlinico Tor Vergata , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6561-5298","authenticated-orcid":false,"given":"Vincenzo","family":"Malagnino","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Systems Medicine, Tor Vergata University , Rome ,","place":["Italy"]},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-0495","authenticated-orcid":false,"given":"Andrea","family":"Ascoli Marchetti","sequence":"additional","affiliation":[{"name":"Vascular and Endovascular Surgery, Department of Biomedicine and Prevention, Tor Vergata University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5311-8203","authenticated-orcid":false,"given":"Arnaldo","family":"Ippoliti","sequence":"additional","affiliation":[{"name":"Vascular and Endovascular Surgery, Department of Biomedicine and Prevention, Tor Vergata University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6938-8627","authenticated-orcid":false,"given":"Marco","family":"Iannetta","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Systems Medicine, Tor Vergata University , Rome ,","place":["Italy"]},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-0333","authenticated-orcid":false,"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Systems Medicine, Tor Vergata University , Rome ,","place":["Italy"]},{"name":"Infectious Disease Clinic, Policlinico Tor Vergata , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2026061308584396100_ofag327-B1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.avsg.2015.07.017","article-title":"Preliminary results from a national enquiry of infection in abdominal aortic endovascular repair (registry of infection in EVAR\u2014R.I.EVAR)","volume":"30","author":"Capoccia","year":"2016","journal-title":"Ann Vasc Surg"},{"key":"2026061308584396100_ofag327-B2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/152660280301000512","article-title":"Endovascular graft infection: preliminary results of an international enquiry","volume":"10","author":"Fiorani","year":"2003","journal-title":"J Endovasc Ther"},{"key":"2026061308584396100_ofag327-B3","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ejvs.2016.09.007","article-title":"Diagnosis of aortic graft infection: a case definition by the management of aortic graft infection collaboration (MAGIC)","volume":"52","author":"Lyons","year":"2016","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026061308584396100_ofag327-B4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/jac\/dki382","article-title":"Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus","volume":"56","author":"FitzGerald","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2026061308584396100_ofag327-B5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1177\/1526602817722018","article-title":"Endograft infection after endovascular abdominal aortic aneurysm repair: a systematic review and meta-analysis","volume":"24","author":"Argyriou","year":"2017","journal-title":"J Endovasc Ther"},{"key":"2026061308584396100_ofag327-B6","first-page":"1","article-title":"Trattamento chirurgico delle infezioni delle protesi aortiche","volume":"22","author":"Canaud","year":"2017","journal-title":"EMC Tecn Chir vasc"},{"key":"2026061308584396100_ofag327-B7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/svas.2001.27874","article-title":"Diagnosis and management of aortic graft infection","volume":"14","author":"Valentine","year":"2001","journal-title":"Semin Vasc Surg"},{"key":"2026061308584396100_ofag327-B8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejvs.2019.10.016","article-title":"Editor's choice - European Society for Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of vascular graft and endograft infections","volume":"59","author":"Chakf\u00e9","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026061308584396100_ofag327-B9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.hlc.2021.07.026","article-title":"Management and outcomes of proximal aortic graft infection: a systematic review","volume":"31","author":"Chong","year":"2022","journal-title":"Heart Lung Circ"},{"key":"2026061308584396100_ofag327-B10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1469-0691.2011.03618.x","article-title":"Characteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study","volume":"18","author":"Legout","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026061308584396100_ofag327-B11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.avsg.2018.02.038","article-title":"Current evidence on management of aortic stent-graft infection: a systematic review and meta-analysis","volume":"51","author":"Li","year":"2018","journal-title":"Ann Vasc Surg"},{"key":"2026061308584396100_ofag327-B12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00000441-200110000-00011","article-title":"Infectious Diseases Society of America's emerging infections network. Long-term suppressive antimicrobial therapy for intravascular device-related infections","volume":"322","author":"Baddour","year":"2001","journal-title":"Am J Med Sci"},{"key":"2026061308584396100_ofag327-B13","article-title":"Long-term suppressive therapeutic-drug-monitoring-guided dalbavancin therapy for cardiovascular prosthetic infections","volume":"12","author":"Gallerani","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026061308584396100_ofag327-B14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s15010-024-02393-9","article-title":"A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis","volume":"53","author":"Leanza","year":"2025","journal-title":"Infection"},{"key":"2026061308584396100_ofag327-B15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106749","article-title":"Dalbavancin as sequential therapy for infective endocarditis due to gram-positive organisms: a review","volume":"61","author":"Fazili","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026061308584396100_ofag327-B16","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/jcm10081743","article-title":"New-generation antibiotics for treatment of gram-positive infections: a review with focus on endocarditis and osteomyelitis","volume":"10","author":"Bloem","year":"2021","journal-title":"J Clin Med"},{"key":"2026061308584396100_ofag327-B17","author":"STROBE"},{"key":"2026061308584396100_ofag327-B18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.idc.2018.06.003","article-title":"Vascular graft infections: an update","volume":"32","author":"Gharamti","year":"2018","journal-title":"Infect Dis Clin North Am"},{"key":"2026061308584396100_ofag327-B19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0140-6736(91)90321-F","article-title":"Salmonella vascular graft infection","volume":"337","author":"Ward","year":"1991","journal-title":"Lancet"},{"key":"2026061308584396100_ofag327-B20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12879-024-08995-w","article-title":"Brain abscess caused by Actinomyces turicensis in a non-immunocompromised adult patient: a case report and systematic review of the literature","volume":"24","author":"Imeneo","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026061308584396100_ofag327-B21","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11122931","article-title":"Actinomyces spp. Prosthetic vascular graft infection (PVGI): a multicenter case-series and narrative review of the literature","volume":"11","author":"Del Fabro","year":"2023","journal-title":"Microorganisms"},{"key":"2026061308584396100_ofag327-B22","first-page":"181","article-title":"Prosthetic vascular graft infections: diagnosis and treatment","volume":"29","author":"Williamson","year":"1989","journal-title":"Crit Rev Diagn Imaging"},{"key":"2026061308584396100_ofag327-B23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12350-018-1337-1","article-title":"Diagnostic yield of 18F-FDG PET\/CT in suspected diagnosis of vascular graft infection: a prospective cohort study","volume":"27","author":"Bowles","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2026061308584396100_ofag327-B24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejvs.2010.05.016","article-title":"Accuracy of FDG-PET-CT in the diagnostic work-up of vascular prosthetic graft infection","volume":"40","author":"Bruggink","year":"2010","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026061308584396100_ofag327-B25","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1016\/j.wneu.2020.02.085","article-title":"Diagnostic performance of F-18 fluorodeoxyglucose positron emission tomography or positron emission tomography\/computed tomography for differentiation of benign and malignant vertebral compression fractures: a meta-analysis","volume":"137","author":"Kim","year":"2020","journal-title":"World Neurosurg"},{"key":"2026061308584396100_ofag327-B26","doi-asserted-by":"crossref","first-page":"13747","DOI":"10.1038\/s41598-021-93331-4","article-title":"Impact of unknown incidental findings in PET\/CT examinations of patients with proven or suspected vascular graft or endograft infections","volume":"11","author":"Husmann","year":"2021","journal-title":"Sci Rep"},{"key":"2026061308584396100_ofag327-B27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.2967\/jnumed.115.156265","article-title":"18F-FDG PET\/CT for therapy control in vascular graft infections: a first feasibility study","volume":"56","author":"Husmann","year":"2015","journal-title":"J Nucl Med"},{"key":"2026061308584396100_ofag327-B28","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-14-228","article-title":"Factors predictive of treatment failure in staphylococcal prosthetic vascular graft infections: a prospective observational cohort study: impact of rifampin","volume":"14","author":"Legout","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2026061308584396100_ofag327-B29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.amjsurg.2006.04.009","article-title":"Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices","volume":"192","author":"Edmiston","year":"2006","journal-title":"Am J Surg"},{"key":"2026061308584396100_ofag327-B30","doi-asserted-by":"crossref","first-page":"45ii","DOI":"10.1093\/jac\/dkg253","article-title":"Safety and tolerability of linezolid","volume":"51","author":"French","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2026061308584396100_ofag327-B31","article-title":"The effect of fluoroquinolones on aortic aneurysm and dissection","volume":"16","author":"Morales-Ojeda","year":"2024","journal-title":"Cureus"},{"key":"2026061308584396100_ofag327-B32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/cid\/civ311","article-title":"Oritavancin: a long-half-life lipoglycopeptide","volume":"61","author":"Saravolatz","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026061308584396100_ofag327-B33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026061308584396100_ofag327-B34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026061308584396100_ofag327-B35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106960","article-title":"Expert opinion on dose regimen and therapeutic drug monitoring for long-term use of dalbavancin: expert review panel","volume":"62","author":"Senneville","year":"2023","journal-title":"Int J Antimicrob Agents"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag327\/68482245\/ofag327.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag327\/68482245\/ofag327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag327\/68482245\/ofag327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:08:25Z","timestamp":1781453305000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag327\/8703138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag327","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"ofag327"}}